vs
Side-by-side financial comparison of Mirum Pharmaceuticals, Inc. (MIRM) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.
PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $148.9M, roughly 1.7× Mirum Pharmaceuticals, Inc.). Mirum Pharmaceuticals, Inc. runs the higher net margin — -3.8% vs -125.2%, a 121.4% gap on every dollar of revenue. Mirum Pharmaceuticals, Inc. produced more free cash flow last quarter ($5.5M vs $-256.6M).
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.
MIRM vs PCLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.9M | $252.6M |
| Net Profit | $-5.7M | $-316.2M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -114.8% |
| Net Margin | -3.8% | -125.2% |
| Revenue YoY | 49.8% | — |
| Net Profit YoY | 75.9% | — |
| EPS (diluted) | $-0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.9M | — | ||
| Q3 25 | $133.0M | — | ||
| Q2 25 | $127.8M | — | ||
| Q1 25 | $111.6M | $252.6M | ||
| Q4 24 | $99.4M | — | ||
| Q3 24 | $90.4M | — | ||
| Q2 24 | $77.9M | — | ||
| Q1 24 | $69.2M | — |
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $2.9M | — | ||
| Q2 25 | $-5.9M | — | ||
| Q1 25 | $-14.7M | $-316.2M | ||
| Q4 24 | $-23.8M | — | ||
| Q3 24 | $-14.2M | — | ||
| Q2 24 | $-24.6M | — | ||
| Q1 24 | $-25.3M | — |
| Q4 25 | -3.1% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | -13.6% | -114.8% | ||
| Q4 24 | -24.4% | — | ||
| Q3 24 | -14.0% | — | ||
| Q2 24 | -31.1% | — | ||
| Q1 24 | -38.2% | — |
| Q4 25 | -3.8% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | -4.6% | — | ||
| Q1 25 | -13.2% | -125.2% | ||
| Q4 24 | -23.9% | — | ||
| Q3 24 | -15.8% | — | ||
| Q2 24 | -31.6% | — | ||
| Q1 24 | -36.5% | — |
| Q4 25 | $-0.10 | — | ||
| Q3 25 | $0.05 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.49 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-0.52 | — | ||
| Q1 24 | $-0.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $383.3M | $456.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $314.7M | $354.8M |
| Total Assets | $842.8M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $383.3M | — | ||
| Q3 25 | $375.5M | — | ||
| Q2 25 | $304.6M | — | ||
| Q1 25 | $277.7M | $456.8M | ||
| Q4 24 | $280.3M | — | ||
| Q3 24 | $284.4M | — | ||
| Q2 24 | $278.4M | — | ||
| Q1 24 | $302.8M | — |
| Q4 25 | $314.7M | — | ||
| Q3 25 | $292.0M | — | ||
| Q2 25 | $255.2M | — | ||
| Q1 25 | $233.3M | $354.8M | ||
| Q4 24 | $225.6M | — | ||
| Q3 24 | $232.0M | — | ||
| Q2 24 | $229.0M | — | ||
| Q1 24 | $234.6M | — |
| Q4 25 | $842.8M | — | ||
| Q3 25 | $785.1M | — | ||
| Q2 25 | $725.8M | — | ||
| Q1 25 | $690.2M | $1.2B | ||
| Q4 24 | $670.8M | — | ||
| Q3 24 | $667.9M | — | ||
| Q2 24 | $660.8M | — | ||
| Q1 24 | $652.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.1M | $-245.6M |
| Free Cash FlowOCF − Capex | $5.5M | $-256.6M |
| FCF MarginFCF / Revenue | 3.7% | -101.6% |
| Capex IntensityCapex / Revenue | 0.4% | 4.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.1M | — | ||
| Q3 25 | $39.7M | — | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $-2.0M | $-245.6M | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | $15.2M | — |
| Q4 25 | $5.5M | — | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $11.9M | — | ||
| Q1 25 | $-2.0M | $-256.6M | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $3.8M | — | ||
| Q2 24 | $-4.6M | — | ||
| Q1 24 | $15.2M | — |
| Q4 25 | 3.7% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -1.8% | -101.6% | ||
| Q4 24 | -5.1% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | -5.9% | — | ||
| Q1 24 | 22.0% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | 4.3% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 13.66× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MIRM
| Livmarli | $106.4M | 71% |
| Bile Acid Medicines | $42.5M | 29% |
PCLA
| Revenue from product | $179.1M | 71% |
| Revenue from SaaS, Maintenance and others | $42.4M | 17% |
| Revenue from product – related party | $31.0M | 12% |
